Summary. Degradation of 125I-iodoglucagon by human mononuclear cell preparations including one containing 18%-27% monocytes, one consisting of 97% pure monocytes and one consisting of 98% lymphocytes was examined. Intact cells were incubated with 125I-iodoglucagon and degradation assessed by measuring an increase in trichloroacetic acid soluble products or in non-immunoprecipitable products. The preparation consisting of intact lymphocytes did not degrade glucagon. Glucagon was degraded by preparations containing monocytes and this degradation increased with time. No difference between monocyte degradation as measured by trichloroacetic acid or immunoprecipitation was found. Degradation by intact monocytes and by mononuclear homogenates increased sixfold from 4~ to 37~ Subcellular fractionation demonstrated that the majority of the neutral glucagon degrading activity was in the 100,000 g supernatant (cytosol). Kinetic analyses gave Km values of 1.1 x 10-5 tool/l, 7.5 x 10 -6 tool/l, and 1.2 x 10 -5 mol/1 for glucagon degradation by intact mononuclear cells, homogenates, and cytosol, respectively. Inhibitor studies indicated a sulphydryl dependent enzyme was involved in glucagon degradation by both intact cells and cytosol. The monocyte appeared to be the cell responsible for degradation of glucagon by mononuclear cell preparations. The degradation of glucagon under physiological conditions by intact monocytes was mediated by a neutral proteolytic enzyme, primarily localized in the cytosol.
tease.
The actions of glucagon on sensitive tissues are initiated by binding of the hormone to specific plasma membrane receptors. Activation of the adenylate cyclase system follows the interaction of the hormone-receptor complex giving rise to a cascade of phosphorylation reactions inside the cell which result in the characteristic metabolic response to glucagon [1] [2] [3] . Tissues known to be responsive to glucagon include adipocytes and hepatocytes. Recant and co-workers have demonstrated that human mononuclear leucocytes are capable of specifically binding glucagon [4, 5] . Mononuclear cells are not classically considered to be glucagon sensitive and therefore the significance of these receptors is unknown.
The fate of glucagon bound to responsive tissues is not well known although the hormone can be degraded by a variety of cellular and circulating proteases. In this study, the degradation of glucagon by human mononuclear cell preparations was investigated. Ficoll-Hypaque preparations containing 18%-27% monocytes and a 97% pure monocyte preparation were found to degrade 125I-iodoglucagon. In contrast, a 98% pure lymphocyte preparation possessed negligible glucagon degrading capacity. In addition, glucagon-degrading systems of intact cells and subcellular fractions were examined and partially characterized.
Materials and Methods

Materials
Glucagon was a gift of Dr. R. Chance of Eli Lilly, Indianapolis, Indiana, USA. 125I-iodoglucagon was purchased from New England Nuclear Company, Boston, Massachusetts, USA and was uniformly greater than 95% trichloroacetic acid precipitable and 80% immunoprecipitable. When 125I-iodoglucagon was more than 2 weeks old, it was rechromatographed on Biogel P-30 (Biorad Laboratories, Richmond, California, USA). Chemicals used in the inhibitor studies were purchased from Sigma Chemicals, St. Louis, Missouri, USA and were of reagent grade quality. All other chemicals were purchased commercially and were of reagent grade quality.
Mononuclear Cell Preparations
Approximately 100 ml of heparinized blood were drawn from fasted normal volunteers and mononuclear cells were isolated using Ficoll- 
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Hypaque [6] . This preparation, which contains both lymphocytes and monocytes, was used for all experiments unless otherwise indicated.
To minimize individual differences, each experiment used mononuclear cells freshly isolated from a single subject. The mononuclear cell preparation contained 18%-27% monocytes with the remainder being large lymphocytes. Monocytes were identified by non-specific esterase stain and cell viability was consistently greater than 98% by trypan blue exclusion [7] . For some studies, purified monocytes (97%) were prepared by centrifugal elutriation in the laboratory of Dr.
A. Postlewaite and purified lymphocytes (98%) by a gel filtration technique [8] .
Glucagon Degradation by Intact Mononuclear Cells
Mononuclear cell preparations, as indicated in figure and table legends, were incubated with 10 -~~ mol/1125I-iodoglucagon in 0.1 tool/1 HEPES, 1% bovine serum albumin (pH 7.4) in a total volume of 500 I-d at 37 ~ in a Dubnoff metabolic shaker (Precision Scientific Products, McGraw Park, Illinois, USA) for 30 rain. Aliquots of the incubation mixture were then added to 300 ~1 of buffer modified to 2% bovine serum albumin and centrifuged at 17,000 g for 5 min. After removal of the supernatant, the pellet was washed again with 500 ~1 of buffer. All supernatants were then combined. Supernatants and pellets were counted in a gamma counter (Packard Instruments, Downers Grove, Illinois, USA) at 58% efficiency. Cell associated radioactivity, including both bound and internalized nsI-iodoglucagon, was defined as counts per rain in the pellet divided by counts per min in the pellet plus supernatant x 100. Degradation was assessed by adding 10% trichloroacetic acid to the supernatant until a final concentration of 5% trichloroacetic acid was obtained. The precipitate was separated by centrifuging the mixture at 2500 rev/min and quantifying precipitated intact hormone and soluble degradation products as previously described [9] . To determine if glucagon-degrading activity was leaking from intact mononuclear cells into the incubation mixture, mononuclear cell fractions were incubated in buffer for 30 min, centrifuged, and the supernatant incubated with 125I-iodoglucagon as above.
Assay of Degradation by Immunoprecipitation
Preliminary experiments were performed to determine the amount of rabbit anti-glucagon antiserum (kindly provided by Dr. Joseph Ingraham, Indiana University School of Medicine, Indianapolis, Indiana, USA) necessary for complete precipitation of the 12sI-iodoglucagon.
Mononuclear cell preparations were homogenized in 0.35 mol/1 sucrose in a glass on glass Dounce homogenizer (Arthur H.Thomas Company, Philadelphia, Pennsylvania, USA). The homogenates were then placed in a 500111 volume of HEPES-bovine serum albumin at pH 7.4 and incubated for 30 min at 37 ~ The reaction was terminated by addition of sufficient trichloroacetic acid to achieve a final concentration of 5%. In other studies, subcellular fractions were obtained by centrifuging the homogenates at 500g for 30 rain. The resulting supernatant was then centrifuged at 30,000g for 30min and separated from the pellet. Finally, centrifugation at 100,000g for 30rain yielded a 100,000 g pellet and cytosolic supernatant. Neutral glucagon-degrading activity was determined on each fraction using HEPES-bovine serum albumin buffer (pH 7.4). Acidic or lysosomal activity was measured after treating each fraction with NaAc (0.1 mol/1), NaCI (0.1 mol/1), 0.1% (v/v) Triton X-100 at pH 4.5 for 12 h to lyse the lysosomes [10] .
Km Determinations
Kinetic analyses were performed on glucagon-degrading activity from intact homogenized cells, and cytosol using standard 125I-iodoglucagon (1 x 10 -1~ mol/1) and varying concentrations of unlabelled glucagon to obtain initial rates. The data were analysed by linear regression.
Results
Glucagon Degradation by Intact Cells
The effect of total number of mononuclear cells on the cell association and degradation of glucagon is illustrated in Figure 1 . Both total cell associated radioactivity and degradation were linearly related to cell number. No degrading activity was present in the supernatant after removal of the cells.
Mononuclear cells incubated for various times between 5 and 120 min demonstrated a time-dependent increase in glucagon degradation (Fig. 2) . Extensive metabolism of glucagon is reflected by the 50% degradation seen at 90 rain. In these experiments, prolonged Fig. 2 . Glucagon degradation at increasing incubation times. Mononuclear cells (25XI06 in 500 !-tl buffer as described in Figure 1) were incubated for varying times at 37 ~ The incubation mixture after removal of the cells degraded 20% of the total glucagon degraded by the cells a For 5• cells at 37~ for 30rain. Glucagon concentration 10 -9 mol/l incubation resulted in leakage of degrading activity in the supernatant accounting for about 20% of the total glucagon degraded.
Glucagon degradation was also temperature dependent with very little degradation at 4 ~ and a sixfold increase over a range of 4 ~ -37 ~ (Fig. 3) .
The effect of trichloroacetic acid precipitation on glucagon degradation is shown in Table 1 . Assay of glucagon degradation by either trichloroacetic acid precipitability or by immunoprecipitability gave comparable results. These data suggest that the intact monocyte produced minimal amounts of degraded material which precipitated with trichloroacetic acid but did not react with glucagon antiserum.
Glucagon Degradation by Mononuclear Cell Homogenates
Homogenized mononuclear cell preparations degraded 10-20 times more glucagon than intact cells (see below). Figure 4 shows the effect of cell number on glucagon degradation by homogenates. Very rapid proteolysis was seen with almost complete degradation at 30 min with high cell number concentrations. Degradation appeared to be linearly associated only at low cell numbers and the time course of glucagon degradation reached a plateau at 45 min (data not shown). Similar to the intact cells, degrading activity increased sixfold from 4 ~ to 37 ~ in the homogenates (Fig. 5) .
Subcellular Distribution of Glucagon-Degrading Activity
Neutral and acidic glucagon-degrading activity was measured in the mononuclear cell homogenates as well as the 500 g, 30,000 g, and 100,000 g pellets and in the 100,000 g supernatant (cytosol). Neutral degrading activity was found in each subcellular fraction (Table 2) with 73% located in the cytosolic fraction. Total neutral activity recovered from the subcellular fractions agreed well with the quantity present in the homogenate. Acidic activity is primarily lysosomic in nature and, accordingly, the 500 g pellet contained almost all of the acidic activity with none present in the cytosolic fraction. The fact that recovery of acidic activity in the subcellular fractions was almost double that found in the homogenate is probably due to the removal of cytosolic inhibi- No. Of Homogenized Cells/mL (xlO 6) Pre-incubation for 15 rnin, 5 x 10 6 at 37 ~ 30min. All solutions (pH 7.4) after addition of all components; b 1 X 106 cell equivalents, same conditions Table3. Summary of kinetic constants for glucagon degradation by intact human mononuclear cells and by hornogenates and cytosolic fraction of rnononuclear cells sulin was found to be a competitive inhibitor of the degradation of glucagon by intact mononuclear cells with a K~ value of 3.6 • 10 -7 mol/1 (Fig. 6) tors of lysosomal enzymes in the fractionation process. Note that the neutral glucagon-degrading activity comprised 75% of the total cellular glucagon-degrading activity in these assays.
Kinetics of Glucagon Degradation
Intact mononuclear cells, homogenized mononuclear cells, and cytosol fractions gave linear LineweaverBurke plots for glucagon degradation. Table 3 summarizes the kinetic constants derived by linear regression analysis. Km values of 1.1 xl0 -5mol/1, 7.5 x 10 -6 mol/l and 1.2 x 10 -5 mol/1 were obtained for intact cells, homogenates and cytosol, respectively. In-
Inhibitor Studies
To ascertain the nature of the cellular degrading enzymes, intact cells and cytosol fractions were examined for sensitivity to various inhibitors (Table 4) . N-ethylmaleimide and p-hydroxymercuribenzoate totally inhibited glucagon degradation by both intact cells and cytosol, indicating that the enzymatic systems of both are sulphydryl-dependent. An apparent effect was also seen with EDTA. Chloroquine and lidocaine, known lysosomotrophic agents, inhibited degradation by the cytosol, while only chloroquine was effective against intact cells. These data are difficult to explain as lysosomotrophic effects since the cytosol had no detectable lysosomal activity. Vinblastine, a compound which inhibits microtubule formation, inhibited degradation as did aprotinin and pepstatin (general protease inhibitors). Bacitracin, methylamine and dansylcadaverine functioned analagously to inhibit glucagon degradation by intact cells and cytosolic fraction alike. With the exception of lidocaine, all 12 inhibitors had the same effect on the cytosol as on the intact cells, indicat- ing the importance of cytosolic enzymes in the metabolism of glucagon by intact mononuclear cells.
Several investigators have noted an accumulation of cell-associated radioactivity on target cells treated with enzymatic inhibitors presumably due to the accumulation of undegraded hormone [11, 12] . Chloroquine and lidocaine gave a 45% and 17% increase in cell-associated radioactivity, respectively (Table 5) . Similar results were obtained by Hofmann et al., using insulin and cultured hepatoma cells [13] . Bacitracin, methylamine, and dansylcadaverine did not increase consistently cellular radioactivity. In fact, no correlation was seen between the potency of the inhibitor and the accumulation of cellular radioactivity as shown in Table 5 .
Glucagon Degradation by Monocytes and Lymphocytes
To examine the relative roles of monocytes and lymphocytes in glucagon degradation, highly purified preparations were obtained. A 98% pure preparation of intact lymphocytes did not degrade significant quantities of glucagon. Monocytes (97% pure) were very active in metabolizing glucagon with 3.73x10-14mol/1 degraded in 30 min by 5 x 106 cells.
Homogenized mononuclear cells exhibited 10-20 times the degrading activity of intact cells, indicating that the bulk of the degrading activity was intracellular. However, homogenized monocyte preparations (enriched four to five times) were only two to three times more active in degrading glucagon than intact monocytes (Table 6) . A 98% pure lymphocyte preparation exhibited significant glucagon-degrading activity only when homogenized.
Discussion
Monocytes have been reported to be responsible for specific binding of glucagon in mononuclear cell preparations [5] . In the present study, we have demonstrated that mononuclear cells in general and monocytes in particular degrade glucagon in a time, temperature, and cell-concentration-dependent manner. Subcellular fractionation of mononuclear cells revealed that 73% of the neutral glucagon-degrading activity was in the cytosol, as previously reported for insulin-degrading activity [15] . Quantitatively, neutral activity was three times greater than acidic activity as reported also for liver [16] . Glucagon degrading activity of both intact cells and cytosol fractions was susceptible to the same inhibitors indicating that glucagon degradation by intact cells was a function of cytosolic enzymes, again similar to the liver [16] , but different from kidney [17, 18] . A cytosolic enzyme has been isolated from various animal tissues which degrades both insulin and glucagon [19, 20] . This soluble neutral protease has properties very similar to those of the glucagon degrading activity found in hu-man mononuclear cells and may well be the same enzyme.
Kinetic studies gave similar Km values for glucagon degradation by intact mononuclear cells, homogenates and cytosol. These values are in the same range as those previously reported for liver and kidney membranes [21] and also similar to the values obtained for insulin protease from rat tissues [18, 19] . Recently, a proteolytic cytosolic enzyme has been isolated from human skeletal muscle which degrades glucagon (Km = 1.3 x 10 .5 tool/l) and is competitively inhibited by insulin (K~= 5 x 10 .8 mol/1) [22] . Significantly, glucagon degradation by intact mononuclear cells was competitively inhibited by insulin with a Ki value of 3 x 10-7mol/1. These data suggest that the cytosolic glucagon-degrading system may be identical to that functioning in intact cells and that this enzyme is similar to insulin protease.
Several investigators have suggested that lysosomes are involved in insulin degradation, both from morphological studies and from studies of lysosomotropic agents such as chloroquine [12, 13, 23] . As reported with insulin, we also found increased cell-associated radioactivity and decreased glucagon degradation with lysosomotrophic compounds. However, cytosolic glucagon-degrading activity, which is devoid of lysosomic activity, was similarly inhibited by lysosomotrophic agents such as chloroquine. These data may imply that the cellular degradation of glucagon in the monocyte, although susceptible to lysosomotrophic agents, is primarily mediated by neutral cytosolic proteases or at least by proteases which fractionate into the 100,000 g supernatant. Goldstein and Livingston have reached the same conclusion for insulin degradation by rat adipocytes [24] .
Davies et al. have recently drawn a correlation between the inhibition of transglutaminase and the inhibition of receptor mediated endocytosis [25, 26] . The transglutaminase inhibitors, bacitracin, methylamine, and dansylcadaverine, were tested for their effects on cell-associated radioactivity and on glucagon degradation by mononuclear cells. All three compounds effectively inhibited degradation of glucagon by both intact cells and cytosol but only methylamine gave an increase in cell-associated radioactivity. These data suggest that transglutaminase inhibitors may have multiple cellular effects as reported previously [27] .
In summary, glucagon is rapidly degraded by human monocytes. Cellular glucagon degradation appears to be primarily mediated by a neutral cytosolic sulphydryl-dependent protease(s). This enzyme(s) is similar in the following properties to insulin protease previously identified in other tissue: (1) subcellular location, (2) Km for glucagon degradation, (3) Ki for insulin, and (4) sensitivity to a wide range of inhibitors.
